PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRopivacaine
Ropivacaine
Naropin, Ropivacaine (ropivacaine) is a small molecule pharmaceutical. Ropivacaine was first approved as Naropin on 1996-09-24. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 5 subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Naropin, Ropivacaine (discontinued: Naropin, Ropivacaine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ropivacaine hydrochloride
Tradename
Company
Number
Date
Products
NAROPINFresenius KabiN-020533 RX1996-09-24
11 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
naropinNew Drug Application2024-09-06
naropin naropinNew Drug Application2018-08-02
readyfusor ropivacaineExport only2018-06-22
ropidexunapproved drug other2024-10-04
ropivacaine hydrochlorideANDA2025-03-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postoperative painD010149G89.18
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ropivacaine Hydrochloride, Naropin, Fresenius Kabi Usa
78578022026-11-28DP
78287872025-10-18DP
81629152024-05-23DP
ATC Codes
N: Nervous system drugs
N01: Anesthetics
N01B: Local anesthetics
N01BB: Amide local anesthetics
N01BB09: Ropivacaine
HCPCS
Code
Description
J2795
Injection, ropivacaine hydrochloride, 1 mg
Clinical
Clinical Trials
1881 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.18112543172277522
PainD010146EFO_0003843R5287144161128
Replacement arthroplasty kneeD019645365414092
AnalgesiaD00069865145075
Bone fracturesD050723EFO_0003931T14.8324233870
Nerve blockD009407212194569
Local anesthesiaD000772235163863
OsteoarthritisD010003EFO_0002506M15-M19143272961
AnesthesiaD000758134153859
Conduction anesthesiaD00076511194153
Show 247 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8023813
Spinal anesthesiaD0007751179
Synovial cystD013581M71.3279
HepatectomyD006498189
Musculoskeletal diseasesD0091403258
HypotensionD007022EFO_0005251I95167
Wrist fracturesD000092503S52.54347
Low back painD017116M54.51135
Urinary bladder neoplasmsD001749C67145
Post-dural puncture headacheD051299145
Show 44 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Post-traumatic stress disordersD013313EFO_0001358F43.11348
Traumatic stress disordersD0409211225
Back painD001416M541134
NauseaD009325R11.0134
Plastic surgery proceduresD019651123
RecurrenceD012008123
Dentofacial deformitiesD063169123
HemorrhageD006470MP_0001914R58123
Subarachnoid hemorrhageD013345EFO_0000713I60123
Soft tissue neoplasmsD012983112
Show 20 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Arteriovenous fistulaD001164Q27.3145
Male circumcisionD002944EFO_0003953145
Chronic kidney failureD007676EFO_0003884N18.6134
CraniotomyD003399123
Multiple fracturesD000069076112
Vulvar diseasesD014845112
Uterine myomectomyD063186112
Plantar fasciitisD036981EFO_1001909M72.211
FasciitisD005208HP_0100537M72.911
Clostridium botulinum type aD04701311
Show 5 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aortic valve stenosisD001024EFO_000026644
Thoracic injuriesD013898S20-S2944
Diabetic footD017719EFO_100145944
AcrodyniaD000170EFO_100175644
Cognitive dysfunctionD060825G31.8444
Esophageal neoplasmsD004938C1533
Ventral herniaD006555EFO_1001866K4333
CryptorchidismD003456EFO_0004562Q53.133
CholecystitisD002764K8133
Herpes zosterD006562EFO_0006510B0233
Show 209 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRopivacaine
INNropivacaine
Description
(S)-ropivacaine is a piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond. It has a role as a local anaesthetic. It is a piperidinecarboxamide and a ropivacaine.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Identifiers
PDB
CAS-ID84057-95-4
RxCUI
ChEMBL IDCHEMBL1077896
ChEBI ID8890
PubChem CID175805
DrugBankDB00296
UNII ID7IO5LYA57N (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SCN5A
SCN5A
Organism
Homo sapiens
Gene name
SCN5A
Gene synonyms
NCBI Gene ID
Protein name
sodium channel protein type 5 subunit alpha
Protein synonyms
cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit, hH1, Sodium channel protein cardiac muscle subunit alpha, Sodium channel protein type V subunit alpha, sodium channel, voltage-gated, type V, alpha subunit, Voltage-gated sodium channel subunit alpha Nav1.5
Uniprot ID
Mouse ortholog
Scn5a (20271)
sodium channel protein type 5 subunit alpha (Q9JJV9)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 13,132 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,286 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use